A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect

Biochemical and Biophysical Research Communications

Volumn 400, Issue 4, 2010, Pages 563-568

  Li, Caina ^a   Huan, Yi ^a   Shen, Ning ^a   Ji, Lixia ^a   Sun, Sujuan ^a   Liu, Shuainan ^a   Liu, Quan ^a   Gao, Lihui ^a   Tan, Fenlai ^b   Wang, Yanping ^b   Shen, Zhufang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b Zhejiang Beta Pharma Inc   (China)

Author keywords

DPP IV; GLP 1 receptor activation; Glucagon like peptide 1 analog; Spontaneous type 2 diabetic KKAy mice

Indexed keywords

BPI 3006; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; GREEN FLUORESCENT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; ENZYME INHIBITION; FLUID INTAKE; FOOD INTAKE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HYPERINSULINEMIA; IN VIVO STUDY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REPORTER GENE; SINGLE DRUG DOSE; TRANSACTIVATION;

AMINO ACID SEQUENCE; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED ICR; MOLECULAR SEQUENCE DATA; PEPTIDES; RECEPTORS, GLUCAGON;

MUS;

EID: 77957287509     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.08.103     Document Type: Article

References (25)

1. Garber A.J. Glucagon-like peptide-1-based therapies: new developments and emerging data. Diabetes Obes. Metab. 2008, 10:22-35.
2. Kreymann B., Williams G., Ghatei M.A., Bloom S.R. Glucagon-like peptide-I 7-36: a physiological incretin in man. Lancet 1987, 2:1300-1304.
3. Elliott R.M., Morgan L.M., Tredger J.A., Deacon S., Wright J., Marks V. Glucagon-like peptide-1 (7-36) amide and glucose dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute postprandial and 24h secretion patterns. J. Endocrinol. 1993, 138:159-166.
4. Bullock B.P., Heller R.S., Habener J.F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagons-like peptide-1 receptor. Endocrinology 1996, 137:2968-2978.
5. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc. Natl. Acad. Sci. USA 1992, 89:8641-8645.
6. Fehmann H.C., Hering B.J., Wolf M.J., Brandhorst H., Brandhorst D., Bretzel R.G., Federlin K., Göke B. The effects of glucagon-like peptide-1 (GLP-1) on hormone secretion from isolated human pancreatic islets. Pancreas 1995, 11:196-200.
7. Hellström P.M., Näslund E., Edholm T., Schmidt P.T., Kristensen J., Theodorsson E., Holst J.J., Efendic S. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol. Motil. 2008, 20:649-659.
8. Kim D.H., D'Alessio D.A., Woods S.C., Seeley R.J. The effects of GLP-1 infusion in the hepatic portal region on food intake. Regul. Pept. 2009, 155:110-114.
9. Williams D.L., Baskin D.G., Schwartz M.W. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 2009, 150:1680-1687.
10. Bregenholt S., Møldrup A., Blume N., Karlsen A.E., Nissen Friedrichsen B., Tornhave D., Knudsen L.B., Petersen J.S. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem. Biophys. Res. Commun. 2005, 330:577-584.
11. Tourrel C., Bailbe D., Lacorne M., Meile M.J., Kergoat M., Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002, 51:1443-1452.
12. Wideman R.D., Yu I.L., Webber T.D., Verchere C.B., Johnson J.D., Cheung A.T., Kieffer T.J. Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proc. Natl. Acad. Sci. USA 2006, 103:13468-13473.
13. Kim S.J., Nian C., McIntosh C.H. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 modulate beta-cell chromatin structure. J. Biol. Chem. 2009, 284:12896-12904.
14. Deacon C.F. What do we know about the secretion and degradation of incretin hormones?. Regul. Pept. 2005, 128:117-124.
15. 3)NH]gly-peptides. Org. Lett. 2003, 5:3887-3890.
16. Huan Y., SHEN Z.F. A novel cell model targeted on GLP-1 receptor for application to anti-diabetic candidates screening. Acta Pharmaceutica Sinica 2009, 44:309-313.
17. 2 for receptor interaction and cAMP production. Eur. J. Med. Chem. 2004, 39:473-480.
18. Knudsen L.B., Nielsen P.F., Huusfeldt P.O., Johansen N.L., Madsen K., Pedersen F.Z., Thøgersen H., Wilken M., Agersø H. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 2000, 43:1664-1669.
19. Parlevliet E.T., Schröder-van der Elst J.P., Corssmit E.P., Picha K., O'Neil K., Stojanovic-Susulic V., Ort T., Havekes L.M., Romijin J.A., Pijl H. CNTO736, a novel GLP-1 receptor agonist, ameliorates insulin resistance and inhibits very low density lipoprotein production in high-fat-fed mice. J. Pharmacol. Exp. Ther. 2009, 328:240-248.
20. Tiessen R.G., Castaigne J.P., Dreyfus J.F., Nemansky M., Kruizinga H.H., van Vliet A.A. Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects. Int. J. Clin. Pharmacol. Ther. 2008, 46:443-452.
21. Yin D., Lu Y., Zhang H., Zhang G., Zou H., Sun D., Zhong Y. Preparation of glucagon-like peptide-1 loaded PLGA microspheres: characterizations, release studies and bioactivities in vitro/in vivo. Chem. Pharm. Bull. 2008, 56:156-161.
22. Youn Y.S., Chae S.Y., Lee S., Jeon J.E., Shin H.G., Lee K.C. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Biochem. Pharmacol. 2007, 73:84-93.
23. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 1999, 85:9-24.
24. Gedulin B.R., Nikoulina S.E., Smith P.A., Gedulin G., Nielsen L.L., Baron A.D., Parkes D.G., Young A.A. EX-4 (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005, 146:2069-2076.
25. 8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. J. Pharmacol. Exp. Ther. 2006, 318:914-921.